RxDoctor Payments Data

Evan Gold, MD

Ophthalmology · Needham, MANPI 1760441034

Payments from drug & device makers

$4,457in general payments, 2019–2025

Across 99 payments — averaging $45.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Beaver-visitec International, Inc.$350
  • AbbVie$332
  • Ocular Therapeutix, Inc.$170
  • Amgen$114
  • Aerie Pharmaceuticals, Inc.$59
  • plus $221 from 6 others

What the payments were for

  • Consulting fees$3508%
  • Travel & lodging$120%
  • Food & beverage$4,09592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,457 in reported general payments places this provider in the 75th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$335,903
Medicare patients
1,361
Services billed
2,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine81$102,817
Cyclosporine37$24,718
RhopressaNetarsudil Mesylate42$19,808
Latanoprost1,204$13,582
Prednisolone Acetate333$11,298
CombiganBrimonidine Tartrate/Timolol31$9,338
RocklatanNetarsudil Mesylat/Latanoprost15$9,237
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol54$8,323
XiidraLifitegrast11$7,378
LumiganBimatoprost26$7,032
Alphagan PBrimonidine Tartrate14$6,618
Timolol Maleate196$4,744
Brimonidine Tartrate159$4,013
SimbrinzaBrinzolamide/Brimonidine Tart12$3,044
Ketorolac Tromethamine229$2,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan, Alphagan P$332$125,805152 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$59$29,04557 claims
AlconSimbrinza$3,212$3,04412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Needham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →